The univariate analysis showed no significant difference between the individual exposure groups (corticosteroids, antibiotics, or anticoagulants) and development of post-COVID-19 syndrome. While the multivariate analysis showed that corticosteroid treatment in patients hospitalized for COVID-19 was associated with a significantly smaller chance (OR 0.32, 95% CI 0.11 to 0.90, p = 0.03) of developing post-COVID-19 syndrome. Anticoagulant treatment in patients hospitalized for COVID-19 was associated with a smaller chance (OR 0.55, 95% CI 0.18 to 1.71, p = 0.30) of developing post-COVID-19 syndrome although this effect was not found to be significant. While antibiotic treatment in patients hospitalized for COVID-19 was associated with a greater chance (OR 1.26, 95% CI 0.47 to 3.39, p = 0.65) of developing post-COVID-19 syndrome compared to patients not treated with antibiotics, it was not statistically significant. Combinations of drug treatments showed no significant changes in lessening the chance of developing post-COVID-19 syndrome.